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Members of the Msi family of RNA-binding proteins
have recently emerged as potent oncoproteins in a
range of malignancies. MSI2 is highly expressed in
hematopoietic cancers, where it is required for dis-
ease maintenance. In contrast to the hematopoietic
system, colorectal cancers can express both Msi
family members, MSI1 and MSI2. Here, we demon-
strate that, in the intestinal epithelium, Msi1 and
Msi2 have analogous oncogenic effects. Further,
comparison of Msi1/2-induced gene expression pro-
grams and transcriptome-wide analyses of Msi1/
2-RNA-binding targets reveal significant functional
overlap, including induction of the PDK-Akt-
mTORC1 axis. Ultimately, we demonstrate that
concomitant loss of function of both MSI family
members is sufficient to abrogate the growth of hu-
man colorectal cancer cells, and Msi gene deletion
inhibits tumorigenesis in several mousemodels of in-
testinal cancer. Our findings demonstrate that MSI1
andMSI2 act as functionally redundant oncoproteins
required for the ontogeny of intestinal cancers.
INTRODUCTION
Mammalian orthologs of the Drosophila melanogaster Musashi
RNA-binding protein include Msi1/MSI1 and Msi2/MSI2.2440 Cell Reports 13, 2440–2455, December 22, 2015 ª2015 The AuDrosophila Musashi governs asymmetric cell fate determination
in neuroblasts through translational suppression of mRNAs
encoding a lineage determinant (Nakamura et al., 1994; Okabe
et al., 2001). A similar role for Msi2 in regulating asymmetric
fate determination has been proposed based on analysis of
asymmetric partitioning of the Msi RNA-binding target Numb in
hematopoietic stem cells with Msi2 gain or loss of function (Kha-
ras et al., 2010; Park et al., 2014). Besides a potential role in gov-
erning asymmetric cell division, Msi proteins act as potent onco-
proteins in a number of cancers. In particular, Msi2/MSI2 is a
cooperative oncoprotein in hematopoietic malignancies, where
it sustains a cancer stem cell self-renewal program through inter-
action with a number of mRNA-binding targets (Ito et al., 2010;
Kharas et al., 2010; Park et al., 2014, 2015). Whereas significant
progress has been made in understanding the contribution of
Msi2 to hematopoietic malignancies, very little is known about
the functional contribution of Msi proteins to oncogenic transfor-
mation in other human malignancies and murine tumor models.
In the hematopoietic system, Msi2 is the only Msi family mem-
ber expressed and its expression is largely restricted to the
hematopoietic stem cell compartment. In contrast, Msi1 and
Msi2 are coexpressed in the putative stem cell compartments
of a variety of other tissues including the hair follicle (Su-
giyama-Nakagiri et al., 2006), mammary gland (Clarke et al.,
2003; Katz et al., 2014;Wang et al., 2008), germ cells (Sutherland
et al., 2014), intestinal epithelium (Kayahara et al., 2003; Li et al.,
2014; Potten et al., 2003; Wang et al., 2015), and neural epithe-
lium (Sakakibara et al., 2002). The observation that both Msi1
and Msi2 are coexpressed in these tissues, coupled with an
absence of phenotype upon genetic ablation of either Msi1 orthors
(legend on next page)
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Msi2 (with the exception of compromised brain ventricle forma-
tion in Msi1/ mice), and sequence homology between Msi1
and Msi2 strongly suggests that functional redundancy exists
between Msi family members. This notion is supported by find-
ings where knockdown of Msi2 in ex vivo cultures of Msi1-null
neurospheres inhibits self-renewal (Sakakibara et al., 2002).
Here, we compare the similarities between the oncogenic
properties of Msi1 and Msi2 in the intestinal epithelium. Pub-
lished studies have observed Msi1 expression in both stem cells
of the intestinal crypts and human colorectal cancers (CRCs),
and several studies suggest that Msi1 has mitogenic activity
driven by potentiation of the canonical Wnt- and/or Notch-
signaling pathways (Cambuli et al., 2015; Rezza et al., 2010;
Spears and Neufeld, 2011; Sureban et al., 2008). Like Msi1,
Msi2 is also expressed in the stem cell compartment of intestinal
crypts and is broadly overexpressed in CRC, andMSI2 inhibition
in SW48 and HT29 CRC cell lines has antiproliferative effects
both in vitro and in murine xenografts (Wang et al., 2015). These
findings suggest that Msi1 and Msi2 may have overlapping roles
in promoting transformation of the intestinal epithelium; howev-
er, in vivo gain-of-function studies demonstrated that Msi2, un-
like Msi1, does not potentiate canonical Wnt signaling and has
little to no effect on activity of theNotch pathway aswas reported
for MSI1 in CRC cell lines (Wang et al., 2015). Thus, there is un-
certainty as to whether Msi1 has oncogenic functions in the
intestinal epithelium in vivo and whether Msi1 and Msi2 might
function redundantly in promoting intestinal transformation.
Here, we demonstrate that acute, in vivo Msi1 gain of function
phenocopies that of Msi2, including expansion of intestinal crypt
base columnar stem cells, blocked differentiation, upregulation
of an APC-loss gene expression signature, and activation of
the mTORC1 complex, all in a Wnt-independent manner. Com-
parison of transcriptome profiles derived from either Msi1 or
Msi2 gain of function indicates that these family members are
capable of activating similar gene expression programs, and
comparison of transcriptome-wide, in vivo, Msi1- and Msi2-
RNA-binding analyses reveals a similar repertoire of binding tar-
gets that function in analogous pathways. Ultimately, Msi1/2
loss-of-function experiments demonstrate that the activity ofFigure 1. MSI1 Is Expressed in Colorectal Cancers and Is Sufficient to
(A) MSI1 expression in matched tumor/control sample pairs from TCGA colorect
MSI1 fold changes in tumor/control pairs for 26 individuals is plotted in red (intra-i
control comparisons for 26 pairs of healthy individuals is plotted in gray (inter-ind
(B) Immunohistochemical staining for MSI1 in graded human colorectal cancer s
(C) Immunofluorescence staining ofMsi1 (red) in stem cells of the intestinal crypt c
CreER knockin mice (green; scale = 50 mm).
(D) Immunofluorescence for b-catenin and Msi1 in an adenoma resulting from APC
100 mm).
(E) Design of doxycycline (Dox)-inducibleMsi1 knockin mice harboring a modified
cDNA under control of the tetracycline-responsive element-minimal CMV promo
locus.
(F) Immunofluorescence staining for Ki-67 marking proliferative cells in the intest
(G) Alcian blue staining for goblet cell mucin.
(H) Immunofluorescence staining for the enteroendocrine marker chromogranin
(I) Histological sections showing extension of crypt height and increased crypt fis
t test).
(J) A crypt undergoing fission in Lgr5-eGFP-IRES-CreER knockin mice costained
See also Figure S1.
2442 Cell Reports 13, 2440–2455, December 22, 2015 ª2015 The Authese RNA-binding proteins is required for the initiation and
maintenance of intestinal cancers.
RESULTS
Msi1 Is Expressed in Intestinal Cancers, and Its Forced
Expression Transforms the Intestinal Epithelium
Several studies suggest that MSI1 and MSI2 are broadly ex-
pressed in CRCs (Levin et al., 2010; Li et al., 2011; Wang et al.,
2015), although correlation of MSI expression with stage or
grade is less clear. We sought to confirm MSI1 expression in
gastrointestinal cancers and observed both over- and underex-
pression relative to controls in a number of these malignancies
(Figures 1A, 1B, S1A, and S1B). Interestingly, matched pairs of
colorectal adenocarcinomas and normal adjacent tissue re-
vealed MSI1 expression to be more variable than that of MSI2,
with MSI1 overexpression observed in around half of these ma-
lignancies in comparison to the ubiquitous overexpression of
MSI2 (Figure 1A; Wang et al., 2015). We confirmed prior reports
ofMsi1 expression inmurine crypt base columnar intestinal stem
cells (CBCs) and its upregulation in early adenomas resulting
from loss of heterozygosity of the APC tumor suppressor in the
APCmin/+ mouse model (Potten et al., 2003; Figures 1C and
1D). Given that MSI2 is broadly expressed in CRC and is also up-
regulated upon APC loss, we generated a targeted, single-copy,
doxycycline-inducibleMsi1 gain-of-functionmousemodel (TRE-
Msi1) using genetic loci identical to those used to assess the
consequences of Msi2 gain of function (Wang et al., 2015).
This enables direct comparison between the consequences of
Msi1 and Msi2 activation (Figures 1E, S1C, and S1D). Doxycy-
cline (Dox) administration resulted in broad induction of Msi1
throughout the intestinal epithelium, but not in the underlying
stromal mesenchyme or lacteals (Figure S1E). Control mice
(R26-M2rtTA + Dox) exhibited no differences in Msi1 expression
patterns relative to wild-type (Figure S1E).
Msi1 induction resulted in an expansion of the crypt prolifera-
tive zone and decreased presence of differentiated cells (the
exception being persistence of Paneth cells, possibly due to their
long lifespan and stable positioning at the crypt base; FiguresTransform the Epithelium
al adenocarcinoma (COAD) RNA-seq (total of 26 patients). The distribution of
ndividual comparison). The distribution ofMSI1 fold changes between control/
ividual comparison).
ections (scale = 100 mm).
ostained for the crypt base columnar stem cell marker Lgr5 in Lgr5-eGFP-IRES-
LOH in the APCmin/+mouse and normal villi adjacent to the adenoma (scale =
reverse tetracycline transactivator (M2rtTA) at the ROSA26 locus and theMsi1
ter (TRE/TetOP) targeted to safe-haven chromatin downstream of the Col1a1
inal crypts of control (M2rtTA) and TRE-Msi1 mice 48 hr after Dox induction.
A (scale in F–H = 100 mm).
sion in TRE-Msi1 mice (quantified at right; n = 3 mice; ***p < 0.0005; Student’s
for Msi1 (red) and GFP (green; scale = 50 mm).
thors
Figure 2. Msi1 Induction Expands the Progenitor Cell Compartment and Drives APC Loss and RNA Metabolism Gene Expression Programs
(A) Msi1 induction in TRE-Msi1::Lgr5-eGFP-CreERmice results in an upward expansion of Lgr5-eGFP+ cells and an increase in the absolute frequency of Lgr5-
eGFP+ cells, quantified by flow cytometry (right; n = 3 mice per group; *p < 0.05; Student’s t test; scale = 50 mm).
(B) TRE-Msi1 epithelium transformed by Dox induction for 48 hr revert to a phenotypically normal state persisting 2months after Dox withdrawal (scale = 100 mm).
(C and D) In vitro culture of intestinal organoids derived from TRE-Msi1::Lgr5-eGFP-CreER crypts followed by Dox induction in vitro. Crypt bud length is quantified
in (D) (***p < 0.0005; Student’s t test).
(legend continued on next page)
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1F–1H and S1F–S1I). This caused TRE-Msi1 mice to become
dehydrated, requiring euthanasia after approximately 3 days of
Dox exposure. Msi1 induction also increased crypt fission, and
endogenous Msi1 colocalized with Lgr5+ CBCs at sites of crypt
fission in wild-type mice (Figures 1I and 1J). We next examined
the effects of Msi1 induction on CBCs in TRE-Msi1::Lgr5-
eGFP-CreER mice and observed an upward expansion of the
stem cell zone and a significant increase in the frequency of
Lgr5-eGFP+ CBCs (Barker et al., 2007; Figure 2A). Dox with-
drawal resulted in a reversion of the epithelium to the wild-type
state, which was maintained for several months, indicating
that, upon Msi downregulation, crypt stem cells return to a
niche-dependent homeostatic state (Figure 2B). Further,Msi1 in-
duction in ex vivo cultures of Lgr5-eGFP+ crypts resulted in
increased growth of crypt buds, indicating that the phenotype
is epithelial cell-autonomous (Figures 2C and 2D).
All of the phenotypes resulting fromMsi1 induction are consis-
tent with those observed in response to Msi2 induction and are
also consistent with acute loss of APC (excepting the stable
positioning of Paneth cells, which become mislocalized upon
APC loss; Sansom et al., 2004; Wasan et al., 1998). Thus, Msi1
induction in vivo phenocopies that of Msi2 in otherwise geneti-
cally identical mouse models.
Msi1 and Msi2 Drive Common Gene Expression
Programs and Interact with Common Target Transcripts
We next analyzed changes to the transcriptome resulting from
Msi1 induction (Table S1). Consistent with our phenotypic obser-
vations, unbiased gene set enrichment analysis (GSEA) (Subra-
manian et al., 2005) demonstrates that the APC-loss gene signa-
ture is among the most highly enriched upon Msi1 induction
(Figures 2E and 2F; Table S2). We also observed enrichment of
gene sets related to mRNA processing and translation along
with an inverse correlation between the Msi1-induced gene
expression program and expression profiles induced by the
mTORC1 inhibitor rapamycin (Figures 2G and 2H). All of these
gene signatures were similarly enriched in intestinal epithelium
overexpressingMsi2 (Wang et al., 2015), indicating that the anal-
ogous phenotypes resulting from Msi1 or Msi2 induction are
driven by analogous gene expression programs. We therefore
directly compared Msi1- and Msi2-induced transcriptome pro-
files and observed that 72% of gene expression changes result-
ing from Msi1 induction also occurred upon Msi2 induction
(Figure 3A). Gene ontology (GO) and pathway analysis found
commonly upregulated programs involved in ribosome biogen-
esis, signal transduction, and ErbB signaling, among others
(Table S3). Commonly downregulated programs were broadly
related to oxidative phosphorylation and mitochondrial activity.
Given that Msi1/2 are RNA-binding proteins that act on trans-
lation (Battelli et al., 2006; Katz et al., 2014; Kawahara et al.,(E) Heatmap and hierarchical clustering of transcriptome profiles performed on the
with Dox for 24 hr.
(F–H) Gene set enrichment analysis (GSEA) of the TRE-Msi1 transcriptome identifie
(APC loss up) and suppression of genes downregulated after APC deletion (A
transcriptome profile and the Peng_Rapamycin UP/DOWN gene sets (G) and a
factors upon Msi1 induction (H). FDR, false discovery rate.
See also Tables S1 and S2.
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wide RNA-binding analysis (CLIP-seq) for both endogenous
and inducedMsi1 in the intestinal epithelium to identify direct tar-
gets. Msi1 bound 2,371 transcripts in wild-type crypts, primarily
in 30 UTRs and coding sequences (Figure 3B; Table S4). Upon
Dox administration, ectopic Msi1 became increasingly associ-
ated with intronic sequences, and 91% of transcripts newly
bound upon Msi1 induction (i.e., those transcripts associated
only with ectopic Msi1) were bound in introns (Figures 3B and
S2A). In total, 93% of transcripts bound by Msi1 in wild-type
crypts were also bound in TRE-Msi1 epithelium (Figure 3C).
These binding patterns were consistent with those previously
described for Msi2.
Motif analysis of CLIP targets indicated that Msi1 binds
distinct sequences in introns and coding sequences in compar-
ison to 30 UTRs, and although Msi1-binding motifs were A-U
rich, the previously described Msi1 motif discovered by a
SELEX-based approach ((A/U)U1–3AGU; Imai et al., 2001) was
not among the most significant (Figure 3D). It was, however, sig-
nificant in the data set and was located in the center of
sequence reads containing it, demonstrating that it is a bona
fide motif in vivo (Figures 3D and 3E). Msi1 binding showed
no preference for highly abundant transcripts, and globally,
transcripts newly bound upon Msi1 induction exhibited no
change in their expression levels (Figures S2B and S2C).
Sequence-specific Msi1-RNA interactions were confirmed
using in vitro binding assays incubating recombinant human
MSI1 with RNA oligos containing the consensus motifs identi-
fied by CLIP (Figure S2D).
The large number of intronic binding sites led us to further
investigate Msi1-intronic interaction. Nuclear/cytoplasmic frac-
tionation of wild-type crypts and human CRC cells indicates
that the majority of Msi1 is cytoplasmic, and binding site conser-
vation analysis demonstrates that, whereas all binding sites for
endogenous Msi1 and the UTR and coding sequence sites for
ectopic Msi1 are evolutionarily conserved, intronic binding sites
of ectopicMsi1 are not (Figures 3F and S2E). These data suggest
that intronic binding events for ectopic Msi1 may be largely pro-
miscuous. Consistent with this, analysis of the location of Msi1-
binding sites across introns revealed a preference for interaction
of Msi1 with the 50 intron terminus in wild-type crypts, and this
preference was largely attenuated for ectopic Msi1 (Figure S2F).
This also suggests that some Msi1-intron interactions may be
involved in alternative splicing (Katz et al., 2014; Uren et al.,
2015). We therefore asked how Msi1 binding was related to
exon inclusion/exclusion. Interestingly, Msi1 targets were more
likely to contain exons that exhibited increased inclusion upon
ectopic Msi1 induction than transcripts not bound by Msi1,
further suggesting that Msi1 activity may be associated with
alternative exon inclusion (Figure S3A).intestinal epithelium of three control (M2rtTA) and three TRE-Msi1mice treated
s activation of genes induced by acuteAPC deletion in the intestinal epithelium
PC loss down; F), along with an anti-correlation between the Msi1-induced
n enrichment of expression of mRNA processing, ribosomal, and translation
thors
(legend on next page)
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GO analysis revealed that Msi1 binds transcripts encoding
regulators of RNA metabolism, nucleotide binding, and cellular
respiration consistent with the GSEA analysis of transcriptome
changes (Figure 3G; Table S5). Significantly enriched GO cate-
gories also included protein localization and transport, possibly
reflecting an established role for Msi in governing asymmetric
cell fate determination (Kharas et al., 2010; Nakamura et al.,
1994). These pathways were not enriched in the set of targets
of an unrelated RNA-binding protein Lin28b (Madison et al.,
2013). Consistent with the GSEA and GO analyses, Ingenuity
Pathway Analysis identified pathways involved in cellular respi-
ration, cancer, and Pten-PI3K-AKT-mTORC1 signaling as being
the most significantly represented across the CLIP data sets
(Figure S3B).
Wenext sought todetermine theoverlap in theRNA-bindingac-
tivities ofMsi1 andMsi2 and observed that 69%and 68%of tran-
scripts bound by wild-type Msi1 in their 30 UTR and coding se-
quences, respectively, were similarly bound by Msi2 (Figure 3H).
Similar binding patterns were observed for ectopically induced
Msi1 and Msi2 (Figure S3C). Both Msi1 and Msi2 targets func-
tioned inanalogouspathways, includingRNAmetabolism,protein
localization, and cellular respiration (Figures 3G and S3B; Tables
S5 and S6). Further, overlap of our murine in vivo CLIP data sets
with published RNA-binding data for MSI1 in human transformed
cell lines in vitro (de Sousa Abreu et al., 2009; Uren et al., 2015; Vo
et al., 2012) reveals a significant overlap despite the vast differ-
ences in cellular identity (Figure S4A). These analyses indicate
that Msi1/Msi2 act on a common set of target genes, accounting
for the identical phenotype between Msi1 and Msi2 gain of func-
tion. Given their highly similar RNA-binding activities, we tested
for Msi1-Msi2 protein interaction but failed to detect any by co-
immunoprecipitation, suggesting that either Msi1 orMsi2 are suf-
ficient to act upon target transcripts (Figure S4B).
The transcripts encoding p21 and Numb are among the best-
characterized Msi1 targets (Battelli et al., 2006; Imai et al., 2001),
and we previously observed Msi2 binding to these transcripts in
the intestinal epithelium (Wang et al., 2015). Similarly, these tran-
scripts were bound by ectopically induced Msi1 (Figure S4C).
Msi1 also bound the transcripts encoding the well-established
intestinal tumor suppressors Lrig1 and Bmpr1 (He et al., 2004;
Powell et al., 2012), as we previously observed for Msi2 (Fig-
ure 4A). Interestingly, Lrig1 is a negative regulator of ErbB
signaling, and we observed upregulation of the ErbB pathway
downstream of both Msi1 and Msi2 (Table S3).Figure 3. Msi1 and Msi2 Have Overlapping RNA-Binding Targets
(A) Venn diagram showing the degree of overlap in gene expression changes drive
TRE-Msi2 intestinal epithelium.
(B) Distribution of Msi1-RNA binding events for endogenous Msi1 in wild-type cr
(C) Venn diagram showing the degree of overlap in Msi1 RNA-binding targets wi
(D) Msi1-binding motif identification and distribution in wild-type intestinal crypts
(E) Position of the canonical Msi1 recognition motif previously identified in vitro w
(F) PhastCons analysis of conservation of Msi1-binding sites in the indicated reg
*p < 0.05; **p < 0.005; ***p < 0.0005.
(G) Gene ontology analyses for biological processes and molecular functions that
as well as for gene sets common to both wild-type or ectopic Msi1 and Msi2, or ta
an unrelated RNA-binding protein Lin28b.
(H) Venn diagrams showing overlap in transcripts bound by endogenous Msi1 an
See also Figures S2–S4 and Tables S3, S4, S5, and S6.
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Canonical Wnt Pathway
Msi1 has been reported to bind to and inhibit the function of APC,
a negative regulator of the transcriptional effector or canonical
Wnt signaling, b-catenin (Spears and Neufeld, 2011), and
in vitro studies have posited a role forMsi1 in potentiating canon-
ical Wnt target gene expression (Rezza et al., 2010). Indeed,
we observed binding of the APC transcript; however, we also
observed stronger binding of Msi1 to the Ctnnb1 transcript en-
coding b-catenin (Figure 4A). We confirmed the preference of
endogenous human MSI1 for CTNNB1 versus APC using CLIP-
qRT-PCR, and this binding preference was maintained upon
Wnt pathway stimulation with the GSK3b-inhibitor CHIR 99021
(Figure 4B). 30 UTR luciferase reporter assays confirmed that
MSI1 repress CTNNB1 translation, albeit moderately (Figure 4C).
Similarly, activity of the TOPFlash multimerized b-CATENIN/TCF
reporter was attenuated by MSI1 activity (Figure 4D). To deter-
mine the effects of Msi1 activity on the canonical Wnt pathway
in vivo, we examined APC and b-catenin protein in control and
TRE-Msi1 epithelium and observed no appreciable differences
(Figures 4E–4G). Further, analysis of the expression of direct
b-catenin target genes in TRE-Msi1 epithelium showed no signif-
icant changes upon Msi1 induction (Figure 4H). Thus Msi1, like
Msi2, does not potentiate canonical Wnt signaling in vivo.
Msi1 Activates the PDK-Akt-mTORC1 Axis
One of the major oncogenic pathways downstream of Msi2 is
mTORC1, which becomes activated uponMsi2 binding to its up-
stream inhibitorPten (Wanget al., 2015).Msi1alsobound to the30
UTR of the Pten mRNA, decreasing Pten protein levels (Figures
5A and 5B). Further, MSI knockdown in human CRC cells led to
increased PTEN activity and decreased PIP3 levels (Figures 5C
and S5A–S5C). Downstream of Pten, Msi1 induction activated
the PDK-Akt-mTORC1 axis (Figures 5B and 5D), with increased
phosphorylation of AKT at T308 by PDK1 (PDPK1). AKT phos-
phorylation at S473 by mTORC2, however, showed only a minor
increase, indicating that mTORC1 activation is due to increased
AKT activity via activation of AKT by the PI3K pathway. Consis-
tent with this notion, we observed an increase in the activating
PDK1 autophosphorylation event at S241 (Figure 5D) and
increased phosphorylation of the AKT target c-RAF (S259),
further supporting the activation of AKT downstream of Msi1.
Downstream of mTORC1, there was strong inactivating phos-
phorylation of the translational inhibitor 4EBP1, resulting inn by Msi1 versus Msi2 induction in transcriptome profiles of the TRE-Msi1 and
ypts (left) and induced Msi1 in TRE-Msi1 intestinal epithelium (right).
ld-type crypts and in TRE-Msi1 intestinal epithelium.
. The fifth motif represents the motif previously identified by selex in vitro.
ithin CLIP-seq reads containing that motif.
ions of Msi1 target transcripts. Error bars represent 95% confidence intervals;
are significantly enriched in Msi1/TRE-Msi1 or Msi2/TRE-Msi2 CLIP data sets,
rgets unique to Msi1/TRE-Msi1 or Msi2/TRE-Msi2, as well as targets bound by
d Msi2 in wild-type crypts.
thors
Figure 4. Effects of Msi1 on Wnt Pathway Activity
(A) CLIP-seq tracks showing endogenous (WT) and ectopically induced Msi1-binding target transcripts.
(B) CLIP-qRT-PCR analysis of endogenous MSI1 binding to 30 UTRs of APC and CTNNB1 (b-CATENIN) in HEK293 cells in the absence (Ctrl) or presence of the
GSK3b inhibitor CHIR99021 (CHIR) (n = 3). ***p < 0.0005; Student’s t test.
(C) Luciferase reporter assays in HEK293 cells upon lentiviral shRNA knockdown of MSI1 (using pSico) or MSI1 overexpression (using pcDNA), shown for
constructs containing the CTNNB1 and NUMB 30 UTRs (n = 3; *p < 0.05; ***p < 0.0005; Student’s t test).
(legend continued on next page)
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activation of the translational initiation factor eIF4E (Figure 5D).
Examination of the levels and spatial distribution S6 phosphory-
lation (as an ultimate readout of S6 kinase activity downstream
of mTORC1) revealed a dramatic induction and expansion
throughout the entire epithelium upon Msi1 induction (Figures
5B and 5E). Thus, activation of the PDK1-AKT axis downstream
of Pten byMsi1 contributes to the observed increase inmTORC1
activity in the intestinal epithelium. To confirm the functional
importance of mTORC1 activity for the Msi1-driven phenotype,
we pre-treated TRE-Msi1 mice with rapamycin prior to inducing
Msi1 with Dox. Rapamycin treatment blocked crypt fission, crypt
height expansion, and hyperproliferation in the presence of
ectopic Msi1 activity, confirming the functional importance of
the mTORC1 complex downstream of Msi1 (Figures 5F–5H).
Msi Activity Is Required for Intestinal Tumorigenesis
The data thus far establish that Msi1 activity is sufficient to trans-
form the intestinal epithelium in a manner analogous to Msi2 and
that these two RNA-binding proteins act on a similar set of target
transcripts and affect analogous downstream pathways. If Msi1
and/or Msi2 act as oncoproteins in intestinal cancers, our data
predict that the expression of one or the other would be sufficient
to drive malignancy. We therefore assessed expression ofMSI1
andMSI2 in a panel of human CRC cells and found that, whereas
MSI2 was consistently expressed across all cell lines,MSI1 was
coexpressed only in a subset and was frequently expressed at
levels lower than those observed in normal human colon (Fig-
ure 6A). This pattern is precisely what we would predict from
TCGA data analysis of paired tumor/adjacent normal tissue (Fig-
ure 1A; Wang et al., 2015). We thus inhibited MSI1 alone or in
combination with MSI2 and/or b-CATENIN in several CRC cell
lines. MSI1 inhibition alone had an antiproliferative effect in
some lines, but not others (Figure 6B), and this effect could not
be predicted by levels of MSI1 expression relative to MSI2.
Concomitant inhibition of both MSI1/MSI2 significantly inhibited
growth of all cell lines analyzed, and additional inhibition of
b-CATENIN blocked tumor cell growth more effectively than
b-CATENIN or MSI inhibition alone (Figure 6B). Immunoblotting
for MSI1 and nuclear (transcriptionally active) b-CATENIN indi-
cates that MSI and b-CATENIN act in parallel pathways, as
b-CATENIN knockdown has no major effect on MSI1 protein
levels and vice versa (Figures 6C and S6A). We further confirmed
that MSI inhibition abrogated the growth of tumor xenografts
from RKO and HCT116 cells and that addition of b-CATENIN in-
hibition synergized with MSI inhibition to completely block tumor
growth (Figures 7A–7D, S6B, and S6C).
These findings suggest that MSI activity is required for the
maintenance of CRC growth. To test this in a more physiologi-
cally relevant setting and to address the importance for Msi ac-(D) Luciferase reporter assays in HCT116 cells for canonical Wnt pathway activat
upstream of luciferase or the control FOPflash reporter with mutated binding sites
(E) Immunofluorescence staining of APC protein in control (M2rtTA) and TRE-Ms
(F) Immunoblotting for APC in control (M2rtTA) and TRE-Msi1 epithelium.
(G) Immunohistochemical staining for transcriptionally active (nuclear) b-cateni
100 mm).
(H) Box plot showing expression levels of known direct b-catenin target genes (ful
(M2rtTA) and TRE-Msi1 mice (n = 3).
2448 Cell Reports 13, 2440–2455, December 22, 2015 ª2015 The Autivity in tumor initiation, we examine tumorigenesis in genetic
models of Msi loss in vivo. First, we generated compound
Msi1flox/flox::VillinCreER::APCmin/+ (Msi1/), Msi2flox/flox::
VillinCreER::APCmin/+ (Msi2/), and Msi1flox/flox::Msi2flox/flox::
VillinCreER::APCmin/+ (Msi-DKO) mice enabling individual or
concomitant ablation of the two Msi genes throughout the
epithelium by tamoxifen-mediated activation of a Villin-CreER
allele (el Marjou et al., 2004; Figures S7A–S7C). Acute deletion
of Msi1 in otherwise wild-type mice had no effect on Msi2
expression and vice versa (Figure S7D). To study the effects of
Msi loss on tumorigenesis, Msi genes were deleted alone or
concomitantly followed by maintaining mice on a low protein
diet to promote adenoma formation upon loss of heterozygosity
at the APC locus. Individual deletion of either Msi1 or Msi2 had
no effect of tumor burden in theAPCminbackground (Figure S7E).
In contrast, MsiDKO mice had a significant reduction in tumor
burden relative to controls (Figure 7E). One hundred percent
(68/68) of residual tumors forming in MsiDKO mice were found
to have escaped recombination at one or more of the floxed
Msi alleles, and thus Msi/ tumors were never observed (Fig-
ure 7F). These data strongly indicate that Msi proteins act redun-
dantly as oncogenes, with the presence of either Msi1 or Msi2
being sufficient to support tumorigenesis upon APC loss.
Whereas the APCmin/+ model is relevant to human disease in
that spontaneous loss of APC is found in the vast majority of hu-
man CRC (Kinzler et al., 1991; Miyoshi et al., 1992; Nagase et al.,
1992), the mouse model differs from the human condition in that
tumors are primarily localized to the small intestine rather than
colon, and they rarely progress to malignant adenocarcinoma.
We therefore examined tumor formation in the AOM-DSS model
of inflammation-driven colorectal adenocarcinoma (De Robertis
et al., 2011). Thismodel is clinically relevant as chronic inflamma-
tion is a leading indicator of CRC risk (van Hogezand et al., 2002).
Experimental and control mice were given a single dose of the
mutagen azoxymethane (AOM), followed by cycles of the inflam-
matory agent dextran sodium sulfate (DSS) to drive formation of
colorectal adenocarcinomas (Figure S7F). As expected, colo-
rectal adenocarcinomas reproducibly formed in control mice
(Figures 7G–7I and S7G). In contrast, Msi-DKO mice were
completely resistant to tumorigenesis in this model with zero tu-
mors forming (Figures 7G–7I and S7G). Taken together, our find-
ings demonstrate the Msi1 and Msi2 act as potent, redundant
oncoproteins whose activity is required for the initiation and
maintenance of cancers of the intestinal epithelium.
DISCUSSION
The Msi family of RNA-binding proteins has been implicated in
oncogenic transformation in a number of organ systems, throughion using the TOPflash reporter with multimerized b-catenin/TCF-binding sites
and empty vector or MSI1 overexpression (n = 3; **p < 0.005; Student’s t test).
i1 mice 48 hr after Dox administration (scale = 100 mm).
n in crypts of control (M2rtTA) and TRE-Msi1 transformed intestine (scale =
l gene list in Experimental Procedures) in total intestinal epithelium from control
thors
Figure 5. Msi1 Functions Through the PDK-Akt-mTORC1 Axis
(A) CLIP-seq track showing Msi1 binding to the 30 UTR of the Pten tumor suppressor mRNA.
(B) Immunoblotting for Pten and S6 phosphorylation upon Msi1 induction in the intestinal epithelium.
(C) PTEN enzymatic activity measured by immunoprecipitation followed by ELISA upon knockdown of MSI1 in 293T cells (**p < 0.005; Student’s t test).
(D) Immunoblot analysis of the PI3K-AKT-mTORC1 pathway downstream of Pten in the intestinal epithelium of two control and two TRE-Msi1mice treated with
Dox for 24 hr.
(E) Immunofluorescence for phosphorylation of S6 by the mTORC1 target S6 kinase in control and TRE-Msi1 transformed intestinal epithelium (scale = 200 mm).
(F–H) Rapamycin treatment rescues TRE-Msi1-induced transformation of the intestinal epithelium. Mice treated with rapamycin for 3 days prior to Dox
administration exhibit decreased crypt fission (F) and a block in crypt height expansion (G; *p < 0.05; **p < 0.005; ***p < 0.0005; Student’s t test). (H)
Immunofluorescence staining for Ki67 of Dox-induced TRE-Msi1mice with or without rapamycin treatment (scale = 100 mm). Brackets indicate the height of the
crypt proliferative zone.
See also Figure S5.
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Figure 6. MSI1 and MSI2 Promote Human
Colorectal Cancer Cell Growth
(A) Expression ofMSI1 andMSI2 in three wild-type
human colon biopsies and a panel of colorectal
cancer cell lines, interrogated with two distinct
primer sets for each MSI gene. HCT116 and
HCT116 WT are the same cell line, procured from
distinct sources (see Experimental Procedures).
(B) Growth of human colorectal cancer cell lines
upon shRNA knockdown of MSI1, MSI1 and MSI2,
MSI1 and b-CATENIN, and MSI1 and 2 and
b-CATENIN (**p < 0.005; ***p < 0.0005; Student’s t
test).
(C) Immunoblotting validating knockdown of MSI1
and transcriptionally active (nuclear) b-CATENIN
in RKO and SW48 cells. Of note, b-CATENIN
knockdown does not affect MSI1 levels and MSI1
knockdown does not significantly affect nuclear
b-CATENIN levels.
See also Figure S6.a number of proposed downstream mechanisms. In particular,
several RNA-binding targets have been proposed to mediate
the oncogenic function of Msi1, including the transcripts encod-
ing p21, Numb, APC, and others (Battelli et al., 2006; Cambuli
et al., 2015; Imai et al., 2001; Sanchez-Diaz et al., 2008; Spears
and Neufeld, 2011; Sureban et al., 2008; Uren et al., 2015; Vo
et al., 2012). These mechanistic studies, however, were con-
ducted using transformed cell lines in vitro or constitutive,
random integrant gain-of-function transgenesis. In contrast,
in vivo transcriptome-wide RNA binding analyses for Msi1 and
Msi2 suggest that the reality is far more complex, with Msi inter-
acting with hundreds to thousands of transcripts.
Although published studies have focused largely on Msi1,
the second mammalian Msi family member, Msi2 has recently2450 Cell Reports 13, 2440–2455, December 22, 2015 ª2015 The Authorsemerged as a potent oncoprotein. In the
hematopoietic system, Msi2 is the only
Msi family member expressed, and its ac-
tivity is required for hematopoietic stem
cell self-renewal (Parket al., 2014). Further,
oncogenic Msi2 activity promotes aggres-
sive leukemias, in the context of acutemy-
elogenous leukemia (AML), mixed-lineage
leukemia (MLL), and chronic myelogenous
leukemia (CML), where it drives chronic
phase disease into the more-aggressive
blast crisis phase characterized by a
more stem-cell-like gene expression pro-
file. Interestingly, in the hematopoietic sys-
tem, the effects of Msi2 appear to be
largely independent of the previously iden-
tified Msi1 RNA-binding targets encoding
Numb and p21 (Kharas et al., 2010; Park
et al., 2014, 2015). Rather, Msi2 appears
to be working through the TGF-b, Hoxa9,
Ikzf2, and Myc mRNAs, as well as through
a more-general function in regulating RNA
biogenesis in the hematopoietic lineage.In the intestinal epithelium, Msi2 governs RNA biogenesis and
also has potent oncogenic properties consistent with observa-
tions in the hematopoietic system (Wang et al., 2015). In contrast
to the hematopoietic system, however, Msi2 bound to several
transcripts encoding well-established colorectal tumor suppres-
sors, including the negative regulator of ErbB-signaling Lrig1, as
well as Bmpr1a and Pten (Goel et al., 2004; He et al., 2004, 2007;
Howe et al., 2001; Marsh et al., 2008; Naguib et al., 2011; Powell
et al., 2012; Wang et al., 2015). Interestingly, the known Msi1-
binding targets encoding p21 and Numb were found to bind
Msi2 in vivo; however, Msi2 induction does not elicit a strong up-
regulation of the Notch pathway, nor does Msi2 potentiate activ-
ity of the canonical Wnt pathway as proposed for Msi1 in cell cul-
ture models. Instead, the major oncogenic effects of Msi2 in vivo
Figure 7. MSI1/Msi1 and MSI2/Msi2 Cooperate to Promote Tumor Growth In Vivo
(A and B) Growth of RKO cell xenografts upon MSI or b-CATENIN shRNA knockdown (A), with tumors shown after dissection upon termination of the
experiment (B).
(C and D) Growth of RKO cell xenografts upon combined knockdown of MSI proteins alone or with b-CATENIN knockdown (C), with tumors shown after
dissection upon termination of the experiment (D; **p < 0.005; ***p < 0.0005; Student’s t test).
(legend continued on next page)
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appears to be activation of mTORC1, a complex dispensable for
intestinal function but known to be required for intestinal tumor-
igenesis downstream of APC loss (Faller et al., 2015; Fujishita
et al., 2008). Thus, there exist discrepancies between the pro-
posed oncogenic functions of Msi1 in CRC cells (e.g., suppres-
sion of p21, Numb, and APC translation and potentiation of
Wnt signaling) and the acute oncogenic consequences of Msi2
gain of function in vivo (RNA metabolism and mTORC1 activa-
tion). Whether these discrepancies represent actual biological
differences between the activity of the two Msi family members
or differences between the in vitro and in vivo model systems
were not understood.
Here, we generated a single-copy, inducible Msi1 mouse
model using genetic loci and strains identical to those previously
used for Msi2 induction in vivo, enabling a direct comparison of
the oncogenic consequences of acute gain of function of the two
Msi family members. Remarkably, Msi1 induction elicits the
identical phenotypic transformation of the intestinal epithelium
observed for Msi2 through interaction with a largely common
repertoire of transcripts. Interestingly, we observed that Msi1
did bind to the APC mRNA as reported in vitro; however, we
observed a stronger interaction between Msi1 and the Ctnnb1
mRNA, suggesting that Msi1 might regulate the canonical Wnt
pathway. However, in contrast to prior reports, we found no ev-
idence that Msi1 potentiates Wnt pathway activity either in vitro
or in vivo, using either human or mouse MSI1/Ms1, consistent
with our observation that MSI1/2 knockdown in human CRC
cells does not significantly affect levels of nuclear b-CATENIN.
Further, the observation that b-CATENIN knockdown does not
affect MSI levels supports a model in which the oncogenic activ-
ities of MSI and b-CATENIN lie in parallel pathways.
These data indicate that Msi1 and Msi2 function redundantly,
leading to the prediction that Msi proteins can act interchange-
ably as oncogenes in CRC. Indeed, dual inhibition of both MSI
proteins is required to fully abrogate tumor growth in CRC cell
lines. Interestingly, the dependence of these cells onMSI activity
appears to be independent of underlying genetic driver muta-
tions, as MSI inhibition was effective in blocking growth of
RKO cells (mutations in BRAF, PIK3CA, and microsatellite insta-
bility), SW48 cells (mutations in APC and microsatellite insta-
bility), HCT116 (mutations in KRAS, PIK3CA, TP53, b-CATENIN,
and microsatellite instability), and LoVo cells (mutations in
KRAS, APC, and microsatellite instability; Ahmed et al., 2013).
This observation is similar to what was previously observed for
MSI2 in human leukemias, where MSI2 upregulation and subse-
quent oncogene addiction occurs regardless of underlying
genetic mutation (Kharas et al., 2010).(E) Frequency of intestinal adenomas in APCmin/+ mice with or without deletion o
Student’s t test; n = 5–6 mice per group).
(F) Representative immunofluorescence micrographs of residual tumors inMsi1/2
expression (scale = 100 mm). The graph at right depicts number of residual tumors
Msi immunoreactivity (100% or 68/68 total residual tumors scored positive).
(G) Frequency of inflammation-driven colorectal adenomas/adenocarcinomas inm
in Msi1/2flox/flox::Villin-CreER mice (***p < 0.0005; Student’s t test; n = 6 mice per
(H) Photographs of distal colon resected from control (left) and Msi1/2 double kn
(I) Representative H&E histological section of a colorectal adenocarcinoma resulti
gene function exhibited normal colon morphology after the AOM-DSS protocol (
See also Figure S7.
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that MSI2 may be the dominant MSI family member in driving
these malignancies, as MSI2 upregulation is essentially ubiqui-
tous in CRC, whereas MSI1 upregulation is observed only in a
subset of human tumor samples and CRC cell lines. Why MSI2
is preferentially expressed relative to MSI1 remains unclear.
Ultimately, the current study demonstrates that both Msi fam-
ily members elicit an analogous transformation of the intestinal
epithelium, with identical phenotypic changes, highly similar
gene expression profiles, and overlapping RNA-binding targets.
Further, concomitant loss of both Msi family members was suf-
ficient to abrogate tumorigenesis in both human and murine
models, clearly demonstrating the critical importance of these
RNA-binding proteins to the ontogeny of CRCs. Our findings
serve as a basis for exploring the mechanisms through which
MSI proteins promote human cancers and highlight the critical
importance of addressing the role of both family members
when studyingMSI function and consideration of their redundant
function for development of MSI inhibitors.
EXPERIMENTAL PROCEDURES
Generation of TRE-Msi1 Mice
All procedures involving mice were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania (Animal
Welfare Assurance reference number A3079-01; approved protocol no.
803415 granted to Dr. Lengner) and were in accordance with the guidelines
set forth in the Guide for the Care and Use of Laboratory Animals of the
National Research Council of the NIH. Euthanasia was performed using
controlled flow carbon dioxide administration followed by cervical dislocation.
The murine Msi1 cDNA (a kind gift from Dr. Joseph Verdi, Maine Medical
Center Research Institute) was cloned into the unique EcoRI restriction site
of the pBS31 vector containing a PGK promoter followed by an ATG start
codon and an FRT recombination site, followed by a splice acceptor-double
polyA cassette, the tetracycline operator with a minimal CMV promoter, the
unique EcoRI site, and an SV40 polyadenylation signal. The pBS31-Msi1 vec-
tor was then electroporated along with a Flpe recombinase-expressing vector
into KH2 embryonic stem cells harboring the modified reverse tetracycline
transactivator (M2rtTA) targeted to and under transcriptional control of the
ROSA26 locus, as well as an FRT-flanked PGK-neomycinR cassette followed
by a promoterless, ATG-less hygromycinR cassette targeted downstream of
the Collagen1a1 locus. Selection for hygromycin resistance upon flip-in
yielded numerous colonies that were verified for proper recombination at the
Coll1a1 locus by digestion of genomic DNA and Southern blotting with a 30
internal probe, yielding a 6.2-kb wild-type band, a 6.7-kb band for the FRT-
containing knockin allele, and a 4.1-kb band for the successfully flipped-in
Msi1-inducible allele (TRE-Msi1).
CLIP-Seq and CLIP-qRT-PCR
CLIP-seq libraries were made as previously described in Chi et al. (2009) with
modifications. The CLIP-seq procedure used in this study was identical to thatf Msi gene deletion in Msi1/2flox/flox::Villin-CreER::APCmin/+ mice (**p < 0.005;
flox/flox::Villin-CreER::APCmin/+mice showing Msi1 (red), Msi2 (green), or Msi1/2
inMsi1/2flox/flox::Villin-CreER::APCmin/+ that were either positive or negative for
ice treatedwith the AOM-DSS protocol, with or without priorMsi gene deletion
group).
ockout (right) mice at the end of the AOM-DSS protocol.
ng from AOM-DSS treatment in control mice (left). In contrast, mice lacking Msi
right; scale = 200 mm).
thors
used inWang et al. (2015) and is described in detail in the Supplemental Exper-
imental Procedures.
Generation and Verification of Msi Floxed Alleles
Msi1 andMsi2 alleles were targeted using homologous recombination in V6.5
embryonic stem cells. Generation of theMsi2 conditional allele is described in
Park et al. (2014). Targeted (3-lox) clones were isolated after neomycin (G418)
selection, and Southern blotting using external probes flanking both the 30 and
50 targeting arm validated proper insertion of the targeting vector. Three-lox
clones were then transiently electroporated with Cre recombinase and subcl-
oned to identify 2-lox conditional clones. Clones harboring 2-lox (floxed) Msi1
and Msi2 alleles were injected into blastocysts and resulting chimeras back-
crossed to a Black/6 background. Addition of Cre recombinase (either tran-
siently in culture or through intercrossing with Villin-CreER mice) resulted in
deletion of the transcriptional start site and exons 1 and 2 (in the case of
Msi1) or exons 1–4 (in the case of Msi2), generating a 1-lox-null allele that
was validated by Southern blotting and Msi protein loss. Southern blotting
was carried out by digesting genomic DNA overnight, transferring to Hybond
XL membrane (Amersham/GE Healthcare) and hybridizing with a 32P-probe
labeled by random priming (Prime-it II, Agilent Technologies) in Church buffer
at 60C overnight followed by washing with increasing stringency SDS/SSC
buffer and exposure to film.
ForMsi1/2 invivoexpressionanalysis inFigureS7D,Msi1flox/flox::VillinCreERor
Msi2flox/flox::VillinCreERmice were administered five doses of tamoxifen (2 mg/
dose in 100 ml corn oil) when they were 6 weeks old. After a 5-day chase period,
crypt epithelial RNA was isolated andMsi gene expression was analyzed.
Apcmin/+ and AOM-DSS Tumor Models
The Apcmin/+ mice were obtained from JAX lab (stock number: 002020).
Apcmin/+::Msi1/2flox/flox, Apcmin/+::Msi1flox/flox, or Apcmin/+::Msi2flox/flox mice
(n = 6–7 mice per group) with or without the Villin-CreER allele (el Marjou
et al., 2004) were given five doses of tamoxifen (2 mg/dose in 100 ml corn oil)
when they were 6 weeks old and then raised on a low-protein/high-fat diet
(Research Diets; D12079B) for 6 months. Additional series of tamoxifen doses
was given 2 and 4 months post-initiation of high-fat diet to maximize recombi-
nation of floxed Msi alleles. Adenomas were scored by two independent
researchers using a stereomicroscope for Apcmin/+::Msi1/2flox/flox or scored
histologically for Apcmin/+::Msi1flox/flox or Apcmin/+::Msi2flox/flox mice.
For AOM-DSS, control mice were co-housedwith experimental mice and in-
jected with 100 ml of 20 mg/ml1 tamoxifen every day for 5 days (n = 6mice per
group). Two weeks after the final tamoxifen injection, all mice were given a sin-
gle intraperitoneal injection of 10 mgkg1 of AOM. One week later, all mice
received 3% DSS in their drinking water for 7 days and then regular water
for 14 days. Two more cycles of DSS were subsequently administered, with
the third and final cycle reduced to 2.5% DSS. Fecal samples were collected
regularly during the experiment, and mice were observed daily and weighed
weekly. Mice were sacrificed approximately 5 weeks after the last DSS cycle.
Tumors were counted using a stereomicroscope, and colon tissue was subse-
quently fixed for histology.
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